2016-2018 Drug Discovery for Neurodegeneration Conferences

 描述（由申请人提供）：在将基础研究转化为新疗法方面存在有据可查的知识和资源缺口。在制药行业之外，下一代科学领导者很少有机会了解药物发现和开发过程，特别是神经退行性疾病。为了满足这一需求，阿尔茨海默病药物发现基金会（ADDF）开发了年度神经退行性疾病药物发现（DDND）会议，自2007年成立以来，已有1，252名参与者。ADDF请求U13合作协议会议赠款，用于支持其DDND会议，计划于2016年3月在佛罗里达州迈阿密举行，2017年3月在加利福尼亚州圣地亚哥举行，2018年3月在华盛顿，华盛顿特区都会区举行。这些教学会议的目标显然与美国国立卫生研究院2012年和2015年阿尔茨海默病研究峰会上提出的倡议一致：弥合药物发现和神经退行性疾病的知识差距;汇集跨学科科学家，激发技能和学科相结合的新方法;并为这些科学家提供交流思想和资源的网络机会。这些会议将为与会者提供开发新药以治疗和预防神经退行性疾病的基本知识和资源，并将解决与以下子主题相关的挑战：（1）开始药物发现活动;（2）从最后开始：临床前药物开发中的药理学-化学界面;（3）药物发现：从先导到临床候选药物;（4）药物发现：从临床候选药物到临床候选药物。（4）CNS靶点的战略：案例研究实例;（5）商业化战略：将科学转化为产品。讨论将包括相关的例子集中在小分子和生物学发展阿尔茨海默氏症和相关的神经退行性疾病。会议将包括30分钟的演讲，有充足的时间进行问答，该计划将包括网络会议，合作/指导，以及由年轻调查人员提出的海报。关于公私伙伴关系，ADDF将邀请来自学术界、工业界和NIH的22名国际知名科学家担任主席或发言人。我们已组建了一个科学咨询委员会，该委员会已同意在今后三年中参与，以协助会议的发展。预计这些会议每年将为来自不同背景的150名科学家提供服务，包括妇女、少数民族、年轻/初级研究人员和研究生。

 DESCRIPTION (provided by applicant): There is a well-documented knowledge and resource gap in translating basic research into novel therapeutics. Outside of the pharmaceutical industry, there are very few opportunities for the next generation of scientific leaders to learn about the drug discovery and development process in general, and particularly for neurodegenerative diseases. To meet this need, the Alzheimer's Drug Discovery Foundation (ADDF) developed the annual Drug Discovery for Neurodegeneration (DDND) conference, which has reached 1,252 participants since its inception in 2007. The ADDF requests a U13 Cooperative Agreement conference grant for three years of support for its DDND conference, scheduled for March 2016 in Miami, FL, March 2017 in San Diego, CA, and March 2018 in the Washington, D.C. metro area. The goals of these didactic conferences are clearly consistent with the initiatives set forth at the NIH's 2012 and 2015 Alzheimer's Disease Research Summit: to bridge the knowledge gap in drug discovery and neurodegenerative disease; to bring together interdisciplinary scientists to stimulate new ways of combining skills and disciplines; and to provide networking opportunities for these scientists to exchange ideas and resources. These conferences will provide participants with fundamental knowledge and resources on developing new drugs to treat and prevent neurodegenerative diseases, and will address the challenges associated with the following sub-topics: (1) Embarking on a Drug Discovery Campaign; (2) Starting at the End: The Pharmacology-Chemistry Interface in Preclinical Drug Development; (3) Drug Discovery: From Lead to Clinical Candidate; (4) Strategies for CNS Targets: Case Study Examples; and (5) Commercialization Strategies: Developing Science into Products. Discussions will include relevant examples focused on small molecule and biologic development for Alzheimer's and related neurodegenerative diseases. Sessions will consist of 30 minute presentations with ample time for Q&A, and the program will include sessions for networking, partnering/mentoring, and posters presented by young investigators. With respect to public-private partnerships, the ADDF will invite 22 internationally recognized scientists from academia, industry and the NIH to serve as chairs or speakers. We have assembled a Scientific Advisory Committee that has agreed to participate for the next three years to assist in the development of the conferences. It is anticipated that these conferences will serve 150 scientists annually from diverse backgrounds, including women, minorities, young/junior investigators and graduate students.